Frank Struyf

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 16 papers. Top paper: “Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans”.

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Nature(2021)10.1038/s41586-021-03681-2

N/A

10.5DataRank · unranked

353 citations

Jingyou Yu, Jinyan Liu, Abishek Chandrashekar, Erica N. Borducchi, Lisa H. Tostanoski +26 more

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

New England Journal of Medicine(2022)10.1056/nejmoa2117608

N/A

4.6DataRank · unranked

251 citations

Glenda Gray, An Vandebosch, Vicky Cárdenas, Georgi Shukarev, Beatriz Grinsztejn +24 more

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Nature Microbiology(2022)10.1038/s41564-022-01262-1

N/A

2.6DataRank · unranked

93 citations

Adrian B. McDermott, David Benkeser, Sanne Roels, Daniel J Stieh, An Vandebosch +56 more

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Infectious Diseases(2022)10.1016/s1473-3099(22)00506-0

N/A

2.0DataRank · unranked

89 citations

An Vandebosch, Jerald Sadoff, Mathieu Le Gars, Carla Truyers, D. Lowson +95 more

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

The Journal of Infectious Diseases(2023)10.1093/infdis/jiac327

N/A

0.718DataRank · unranked

119 citations

Matthew G Davis, Katie Steenackers, Brandon Essink, Corinne Vandermeulen, Charles Fogarty +17 more

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

Nature Communications(2024)10.1038/s41467-024-53727-y

N/A

0.644DataRank · unranked

21 citations

Ollivier Hyrien, Youyi Fong, David Benkeser, Sanne Roels, Daniel J Stieh +56 more

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19

medRxiv(2021)10.1101/2021.07.05.21259918

N/A

0.464DataRank · unranked

21 citations

Kathryn E. Stephenson, Jerald Sadoff, Jingyou Yu, Aiquan Chang, Makda S. Gebre +12 more

Risk of COVID-19 after natural infection or vaccination

EBioMedicine(2023)10.1016/j.ebiom.2023.104799

N/A

0.396DataRank · unranked

13 citations

Matthew B. Laurens, Ying Huang, Chenchen Yu, Thomas Martin, Carina A. Rodriguez +94 more

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial

EClinicalMedicine(2025)10.1016/j.eclinm.2024.103016

N/A

0.249DataRank · unranked

4 citations

Gloria Aguilar, Nathalie Vaissière, Carla Truyers, Pedro Ylisastigui, Erik Buntinx +15 more

Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial

iScience(2025)10.1016/j.isci.2025.113660

N/A

0.104DataRank · unranked

1 citations

Youyi Fong, Lars van der Laan, Fei Heng, Ying Huang, Yiwen Lu +61 more

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

UNC Libraries(2021)10.17615/phnx-3j92

N/A

0DataRank · unranked

0 citations

Kathryn E. Stephenson, Jingyou Yu, Aiquan Chang, Johan Van Hoof, Sally Shin +26 more

Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting

medRxiv(2021)10.1101/2021.08.25.21262569

N/A

0DataRank · unranked

23 citations

Mathieu Le Gars, Vicky Cárdenas, Georgi Shukarev, Nathalie Vaissière, Dirk Heerwegh +10 more

Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine

Immunological Reviews(2022)10.1111/imr.13088

N/A

0DataRank · unranked

27 citations

Jenny Hendriks, Jerald Sadoff, Martin Ryser, Frank Struyf, Macaya Douoguih +2 more

Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial

medRxiv(2022)10.1101/2022.04.06.22272763

N/A

0DataRank · unranked

12 citations

Adrian B. McDermott, David Benkeser, Sanne Roels, Daniel J Stieh, An Vandebosch +56 more

Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26–vectored vaccines

Journal of Thrombosis and Haemostasis(2024)10.1016/j.jtha.2024.08.019

N/A

0DataRank · unranked

5 citations

Leen Slaets, Esmée Braams, Ilse Scheys, Roy van Heesbeen, Vicky Cárdenas +8 more

Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16–17 Years of Age

Journal of the Pediatric Infectious Diseases Society(2024)10.1093/jpids/piae098

N/A

0DataRank · unranked

0 citations

Mathieu Le Gars, Vicky Cárdenas, Nathalie Vaissière, Jerald Sadoff, Carla Truyers +7 more